Sandoz wins three prizes at Global Generics and Biosimilars Awards

Sandoz has picked up a trio of accolades at the annual Global Generics and Biosimilars Awards, organised by Generics Bulletin.

The firm was named company of the year after a 12-month period in which it met several significant milestone achievements and achieved four quarters of strong growth, driven by a renewed strategic focus.

Its launch of Zarxio won the biosimilar initiative of the year award, with the move making Sandoz the first company to introduce a biosimilar in the US, an achievement that mirrored its similar milestone in Europe nearly a decade ago.

Finally, the US approval and launch of Glatopa as the first generic counterpart to the leading multiple sclerosis therapy Copaxone won regulatory achievement of the year.

The company said the win "further demonstrated Sandoz's commitment to offer patients and payors a full range of therapeutic options".

Parent company Novartis expects Sandoz to achieve high single-digit sales growth in 2015, with a renewed focus on key geographies and portfolio areas set to drive this.